您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > AZD 3965
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
AZD 3965
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
AZD 3965图片
CAS NO:1448671-31-5
规格:98%
分子量:515.5
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议

产品介绍
potent inhibitor of monocarboxylate transporter 1 (MCT1)
CAS:1448671-31-5
分子式:C21H24F3N5O5S
分子量:515.5
纯度:98%
存储:Store at -20°C

Background:

Ki = 1.6 nM for MCT1


AZD 3965 is a potent inhibitor of monocarboxylate transporter 1 (MCT1).


Inhibition of monocarboxylate transporter 1 (MCT1) is currently considered as a promosing therapeutic way to block lactate shuttling in tumor cells lacking monocarboxylate transporter 4.


In vitro: Previous study found that the in-vitro AZD3965 sensitivity varied and was highest in hypoxia. To further support that AZD3965 targeted MCT1, NCIH1048 cells were engineered to inducibly overexpress MCT1. It was found that when MCT1 was overexpressed, the EC50 of AZD 3965 against NCI-H1048 was increased from 0.14 to 10.5 nM, which was consistent with AZD3965 acting through MCT1 inhibition [1].


In vivo: COR-L103 xenograft studies were conducted to test whether the in-vitro effect of AZD3965 could be recapitulated in vivo. COR-L103 tumor-bearing mice were treated with AZD3965 at 100 mg/kg BID for 21 days. The pharmacokinetic analyses showed that AZD3965 at 100 mg/kg BID led to free concentrations of AZD3965 predicted to inhibit lactate transport. Moreover, AZD3965 treatment was able to reduce the growth of CORL103 tumors significantly, though tumor regression was not observed, which was consistent with AZD3965 only targeting the hypoxic fraction of the tumor [1].


Clinical trial: A phase I trial of AZD3965 in patients with advanced cancer is currently recruiting participants [2].


参考文献:
[1] Polanski, R. ,Hodgkinson, C.L.,Fusi, A., et al. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin.Cancer.Res 20(4), (2014).
[2] https://clinicaltrials. gov/ct2/show/NCT01791595 term=AZD+3965&rank=1